Overview

A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

Status:
Completed
Trial end date:
2022-01-25
Target enrollment:
Participant gender:
Summary
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of QL1207 compared to Eylea® in subjects with wet AMD.
Phase:
Phase 3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Aflibercept